$10.93
-0.48-4.21%
Last update: Nov 12, 5:17 PM
Sagimet Biosciences Inc (SGMT) Stock Price, Quote, News & History
SGMTNASDAQ
Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.
You can purchase shares of Sagimet Biosciences (NASDAQ:SGMT) through any online brokerage.
Other companies in Sagimet Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Sagimet Biosciences has a consensus price target of $25.23.
The stock price for Sagimet Biosciences (NASDAQ: SGMT) is $10.6 last updated November 12, 2026 at 5:17 PM EST.
There are no upcoming dividends for Sagimet Biosciences.
Sagimet Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Sagimet Biosciences.
Sagimet Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of...
